Related Experiment Video

Updated: Jun 28, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Acute myocardial infarction complicated by cardiogenic shock: role of mechanical circulatory support

Sanjeev Aggarwal1, Mark S Slaughter

  • 1University of Louisville, Cardiovascular Innovation Institute, Division of Thoracic and Cardiovascular Surgery, Louisville, KY 40202, USA. saggarwal@ucsamd.com

Expert Review of Cardiovascular Therapy
|October 23, 2008
PubMed

Insights

Early revascularization and percutaneous ventricular assist devices (VADs) can improve outcomes for acute myocardial infarction with cardiogenic shock (AMI-CS). However, limited access to these treatments hinders effective management of this critical condition.

Area of Science:

  • Cardiology
  • Medical Devices

Background:

  • Acute myocardial infarction complicated by cardiogenic shock (AMI-CS) is a primary cause of in-hospital mortality in acute coronary syndromes.
  • Current guidelines recommend early revascularization and intra-aortic balloon pump support for AMI-CS patients.

Purpose of the Study:

  • To evaluate the potential benefits of early percutaneous ventricular assist devices (VADs) and revascularization in reducing mortality in AMI-CS.
  • To highlight the limitations in accessing advanced VADs and revascularization procedures.

Main Methods:

  • Review of current treatment guidelines and emerging VAD technologies.
  • Analysis of the advantages and disadvantages of pulsatile and percutaneous VADs.
  • Discussion on the impact of early intervention on patient outcomes.

Main Results:

  • Ventricular assist devices (VADs) offer superior cardiac support compared to intra-aortic balloon pumps, especially when implanted early.
  • Percutaneous VADs can be implanted non-surgically, normalize cardiac index, and may reduce AMI-CS mortality.
  • Pulsatile VADs, while versatile, carry a higher risk of complications.

Conclusions:

  • Early implementation of percutaneous VADs combined with early revascularization holds promise for improving survival rates in AMI-CS.
  • Current limited access to revascularization and VADs, including percutaneous options, impedes effective treatment for AMI-CS patients.

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Related Concept Videos

Blood Pressure Imbalances and Circulatory Shock01:24

Blood Pressure Imbalances and Circulatory Shock

Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...